Overview
Experience the MostComprehensive
Whole Exome Panel
Celemics WES is a comprehensive whole exome panel that covers the target regions of major WES panels in the market. With the target size of 37.1 Mb, the panel does not compromise performance in terms of NGS coverage and uniformity, enabling highly efficient and cost-effective sequencing of the whole human exome.
WES panel also perform well against hard-to-capture regions such as GC-rich regions. Regarding spike-in options, we also have the ability to customize our WES panel according to your needs by including mitochondrial or intronic regions at your request. The panel is also supported by Celemics Analysis Service (CAS), an end-to-end bioinformatics solution.
Features & Benefits
Complete Whole Exome Coverage
WES panel includes all exonic regions of major exome panels (37.1 Mb) with >98% coverage in addition to our proprietary probes that allows flawless capture performance even at ‘hard-to-capture’ regions, like GC-rich region. Experience the market-leading performance of on-target ratio and uniformity of Celemics’ WES panel.
Exclusive Technology
for Market-leading Performance
With Celemics’ proprietary probe and assay design technology, we are competent to provide a robust WES panel with market-leading on-target ratio and uniformity.
For all panels that we design and manufacture, we always validate the panel and sequencing performance by fine-tuning the probe sets and reagents to ensure exceptional capture performance even in ‘hard-to-capture’ region to maximize the efficiency and provide the highest quality possible sequencing data for all our customers.
Superior Performance in the Market
Celemics WES Panel shows exceptional performance compared to other competitor products in both germline and FFPE analysis.
(A) 1-PCT OFF BAIT (higher the better)
(B) Fold 80 base penalty (lower the better)
* Third-party laboratories (Certified Service Providers)
conducted a comparison study between the Celemics WES Panel, Company A and Company I panels. Reference materials NA12878, NA12891, NA12892 for germline analysis, and HD832 for FFPE analysis were used with same amount. Illumina instruments were used for the sequencing. The data from the three panels were downsampled to 5.4 Gb.
Rapid One-Day Protocol
In order to reduce the hands-on and turn-around time for NGS, we have developed Celemics’ original One-Day protocol that does not require any heavy instruments.
Simplify your workflow with alternative methods for sample shearing, concentrating, and even QC and expedite your exome sequencing without compromising data quality.
Newly Developed Same-Day Workflow
Complete Bioinformatics Support and Customization Service
Team of in-house Bioinformaticians have developed an exclusive analysis pipeline to simplify the data analysis process. Customer will simply ‘click’ to upload FASTQ to generate the ‘report’ for finalized analysis.
Different analytic-tiers for clinical interpretations or any other customizable types of analysis can also be supported to meet your analytic requirements.
CAS (Celemics Analysis Service) Workflow
Other Features
Complete Walkaway
Automation
Automate from sample preparation to hybridization on Hamilton, Bravo, or Sciclone.
Flexible Customization
and Modification
Easy gene add-on service to expand your research discovery. ‘Make your own’ custom exome panel by adding spike-in mtDNA or intronic regions of interest.
Flexible Integration with
various NGS Sequencers
Celemics’ blocker and assay optimization technology allows seamless integration with various sequencing platforms (Illumina, MGI, and Thermo Fisher)
Specification
| Target size | 37.1 Mb | |
|---|---|---|
| Covered region | CCDS, RefSeq, Genecode | |
| Multiplexing option | 4 / 8 / 12-plex enrichment | |
| Platform | Illumina, MGI and Thermo Fisher | |
| Uniformity (0.2X mean depth coverage uniformity) |
gDNA | FFPE |
| > 96% | > 95% | |
| On-target (1-PCT OFF BAIT*) |
gDNA | FFPE |
| > 96% | > 95% | |
| Bioinformatics Support |
|
|
Related Products
Circulating Tumor DNA Panel – Colorectal / Lung / Breast Discover the accelerated NGS with Reliable result for variant with ultra low
G-Mendeliome Clinical Exome Sequencing Panel Sensitive Detection of Variants with Clinically Significant Genetic Diseases Overview Features & Benefits Specification Related Products Resources
Celemics Analysis Service Trust CAS with your Bioinformatics Analysis Overview Features & Benefits Workflow Related Products Resources Overview Features & Benefits Workflow
Product-sample Ultimate Exonic Coverage · Simple Workflow and Analysis · Exceptional Performance Overveiw Features & Benefits Specification Related Products Resources Overveiw Features
Resources
Technical Resources
Safety Data Sheets
References
Theranostics
Development of the phenylpyrazolo [3, 4-d] pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor
Lee HJ, Pham PC, Pei H, Lim B, Hyun SY, Baek B, et al. Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor. Theranostics. 2021;11(4):1918–36.
10.7150/thno.48865
–
First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-2 positive gastric cancer with sequential genomic profiling
Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 17(5):491–501.
10.21203/rs.3.rs-254208/v1
British Journal of Cancer
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
Oh HJ, Bae JM, Wen X, Jung S, Kim Y, Kim KJ, et al. p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Br J Cancer. 2019 Apr;120(8):797–805.
10.1038/s41416-019-0429-2